Neucel Specialty Cellulose
Neucel Specialty Cellulose has not claimed their Profile.
Want to better differentiate Neucel Specialty Cellulose between your competitors? Show buyers how.
Why does Neucel Specialty Cellulose win vs. Cognate BioServices?
Show Neucel Specialty Cellulose's primary competitive advantage Show Neucel Specialty Cellulose's competitive differentiationNeucel Specialty Cellulose's alternatives and competitors
See how Neucel Specialty Cellulose compares to similar products. Neucel Specialty Cellulose's top competitors include Cognate BioServices, MetaBiologics, and HumanZyme.
Cognate BioServices provides a range of commercialization services to regenerative medicine, cellular immunotherapy, and advanced cell therapy companies.On February 17t…
Neucel Specialty Cellulose vs. Cognate BioServices
View more in-depth data on:
- Competitors
- Products
- Customer References and more
MetaBiologics manufactures toxins used in healthcare research and in anti-biological weapons research.
Neucel Specialty Cellulose vs. MetaBiologics
View more in-depth data on:
- Competitors
- Products
- Customer References and more
HumanZyme is engaged in the production of large quantities of highly active, pure and authentic human proteins in human cells.
Neucel Specialty Cellulose vs. HumanZyme
View more in-depth data on:
- Competitors
- Products
- Customer References and more
Fusion Antibodies uses technology to rapidly produce fusion proteins from genes and uses these products as antigens for the production and purification of antibodies.
Neucel Specialty Cellulose vs. Fusion Antibodies
View more in-depth data on:
- Competitors
- Products
- Customer References and more
Roka Bioscience is dedicated to developing rapid, highly accurate molecular assays and instrument systems for the Food Safety Industry. The Atlas System represents a ne…
Neucel Specialty Cellulose vs. Roka Bioscience
View more in-depth data on:
- Competitors
- Products
- Customer References and more
- EV
This company, formerly known as Sceptor, is a global diagnostics, biological collection and detection systems company dedicated to improving the quality of life and wor…
Neucel Specialty Cellulose vs. Evogen
View more in-depth data on:
- Competitors
- Products
- Customer References and more
NeoClone is a custom monoclonal antibody company focused on developing high quality antibodies for sale as reagents and establishing partnerships and collaborations to …
Neucel Specialty Cellulose vs. NeoClone
View more in-depth data on:
- Competitors
- Products
- Customer References and more
Cogentus Pharmaceuticals is a privately held specialty pharmaceutical company founded in 2006. Cogentus is committed to becoming a premier developer of innovative, fixe…
Neucel Specialty Cellulose vs. Cogentus Pharmaceuticals
View more in-depth data on:
- Competitors
- Products
- Customer References and more
Transgenomic (NASDAQ:TBIO) is a global biotechnology company that advances personalized medicine in oncology and inherited diseases via its products and services for au…
Neucel Specialty Cellulose vs. Transgenomic
View more in-depth data on:
- Competitors
- Products
- Customer References and more
Charles River Laboratories (NYSE: CRL) provides products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic inst…
Neucel Specialty Cellulose vs. Charles River Laboratories
View more in-depth data on:
- Competitors
- Products
- Customer References and more
- BI
Biomm offers a recombinant human protein production platform.
Neucel Specialty Cellulose vs. Biomm
View more in-depth data on:
- Competitors
- Products
- Customer References and more
- NE
The company's core business is and remains the development and production of Active Pharmaceutical Ingredient and parenteral formulations in the the form of solution an…
Neucel Specialty Cellulose vs. Neon
View more in-depth data on:
- Competitors
- Products
- Customer References and more
Microarray was formed in July 2000, as a joint venture between Manchester Metropolitan University (MMU) and the The University of Manchester. Microarray also offers co…
Neucel Specialty Cellulose vs. Microarray
View more in-depth data on:
- Competitors
- Products
- Customer References and more
Top 10 Neucel Specialty Cellulose competitors
You May Also Like

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.
Adimab is engaged in the discovery, maturation and production of therapeutic human antibodies. Per the company, Adimab integrates all aspects of antibody discovery and sophisticated screening methods, and therefore can rapidly discover high affinity antibodies that also behave well in a formulation and manufacturing context. The company states that their proprietary library design and presentation technology allows Adimab to discover full-length human antibodies with broad epitope coverage, high affinity and therapeutic relevance faster than any current technology.
Biomm offers a recombinant human protein production platform.
EMTech, a spin-off of BiOva, LLC, is researching, developing, and manufacturing technologies for the metabolic enhancement of the enzymes and bacteria used in the fermentation industry. The company's current products and ongoing research projects show applications that enhance productivity in the ethanol, pharmaceutical, beer, wine, and dairy industries.
Aiming to leverage the knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.
Matrix Sensors aims to democratize air quality sensors for a cleaner, healthier, and safer world.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.